Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - memantine hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; lactose monohydrate; croscarmellose sodium; titanium dioxide; hyprolose; microcrystalline cellulose; macrogol 8000 - treatment of the symptoms of moderately severe to severe alzheimer's disease

United States - English - NLM (National Library of Medicine)

strides pharma science limited - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride extended-release tablets, usp is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride is contraindicated in patients on triamterene and amiloride. risk summary there are no human data related to use of potassium chloride extended-release tablets, usp during pregnancy, and animal reproduction studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary the normal potassium ion content of

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - potassium chloride 46,6 mg; sodium chloride 350,7 mg; macrogol 13125 mg; sodium hydrogen carbonate 178,5 mg - powder for oral solution - 13,7 g - sodium chloride 350.7 mg; potassium chloride 46.6 mg; sodium bicarbonate 178.5 mg; macrogol 3350 13125 mg - macrogol, combinations

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - sodium hydrogen carbonate 89,25 mg; macrogol 6562,5 mg; potassium chloride 23,3 mg; sodium chloride 175,35 mg - powder for oral solution - 6,9 g - sodium bicarbonate 89.25 mg; sodium chloride 175.35 mg; potassium chloride 23.3 mg; macrogol 3350 6562.5 mg - macrogol, combinations

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - macrogol 13,125 g; potassium chloride 0,0466 g; sodium chloride 0,3507 g; sodium hydrogen carbonate 0,1785 g - powder for oral solution - 13,125 g - 351 mg - 179 mg - 47 mg - sodium chloride 350.7 mg; sodium bicarbonate 178.5 mg; potassium chloride 46.6 mg; macrogol 3350 13.125 g - macrogol, combinations

United States - English - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride extended-release tablets, usp is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride is contraindicated in patients on triamterene and amiloride. risk summary there are no human data related to use of potassium chloride extended-release tablets, usp during pregnancy, and animal reproduction studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary the normal potassium ion content of

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - macrogol 13,125 g; potassium chloride 0,0466 g; sodium hydrogen carbonate 0,1785 g; sodium chloride 0,3507 g - powder for oral solution - 13,7 g - macrogol 3350 13.125 g; sodium chloride 0.351 g; potassium chloride 0.047 g; sodium bicarbonate 0.179 g - macrogol, combinations

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride extended-release tablets, usp is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride is contraindicated in patients on triamterene and amiloride. risk summary there are no human data related to use of potassium chloride extended-release tablets, usp during pregnancy, and animal reproduction studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary the normal potassium ion content of

United States - English - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride extended-release tablets, usp is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride is contraindicated in patients on triamterene and amiloride. risk summary there are no human data related to use of potassium chloride extended-release tablets, usp during pregnancy, and animal reproduction studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary the normal potassium ion content of

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - macrogol 4000 mg - powder for oral solution in sachet - 4 g - macrogol 4000 4000 mg - macrogol